Oracle has committed $205m to an initial public offering for the DNA sequencing technology developer with a $410m target for its close.

Oxford Nanopore, the UK-based DNA sequencing technology spinout of University of Oxford, has secured software producer Oracle as a cornerstone investor for its initial public offering on the London Stock Exchange.

Oracle will invest £150m ($205m), a commitment representing half of the $410m target Oxford Nanopore has set for the offering.

The companies have also entered into a partnership to explore potential applications for genomic sequencing running on Oracle’s cloud. They expect to tackle large-scale projects spanning drug discovery, healthcare,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn